Brokerages Expect Beam Therapeutics Inc. (NASDAQ:BEAM) to Post -$1.14 Earnings Per Share

Wall Street analysts predict that Beam Therapeutics Inc. (NASDAQ:BEAMGet Rating) will post earnings per share of ($1.14) for the current quarter, Zacks reports. Four analysts have made estimates for Beam Therapeutics’ earnings. The highest EPS estimate is ($0.87) and the lowest is ($1.55). Beam Therapeutics reported earnings per share of ($0.95) in the same quarter last year, which indicates a negative year-over-year growth rate of 20%. The company is expected to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Beam Therapeutics will report full year earnings of ($3.84) per share for the current financial year, with EPS estimates ranging from ($6.29) to ($0.44). For the next financial year, analysts forecast that the firm will post earnings of ($4.96) per share, with EPS estimates ranging from ($7.73) to ($3.65). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Beam Therapeutics.

Beam Therapeutics (NASDAQ:BEAMGet Rating) last posted its quarterly earnings data on Monday, May 9th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.31. Beam Therapeutics had a negative net margin of 714.91% and a negative return on equity of 52.28%. The business had revenue of $8.40 million during the quarter, compared to the consensus estimate of $44.15 million. During the same quarter last year, the company posted ($3.35) earnings per share. The firm’s quarterly revenue was up 139900.0% compared to the same quarter last year.

BEAM has been the subject of a number of research analyst reports. Wedbush decreased their price objective on shares of Beam Therapeutics from $159.00 to $152.00 and set an “outperform” rating for the company in a report on Monday, February 28th. Credit Suisse Group started coverage on shares of Beam Therapeutics in a research note on Thursday, April 28th. They issued a “neutral” rating and a $62.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $122.50.

In related news, CEO John M. Evans sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, April 28th. The shares were sold at an average price of $37.98, for a total transaction of $1,139,400.00. Following the completion of the transaction, the chief executive officer now owns 1,118,520 shares of the company’s stock, valued at $42,481,389.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO John M. Evans sold 6,261 shares of the business’s stock in a transaction that occurred on Thursday, March 31st. The shares were sold at an average price of $59.11, for a total transaction of $370,087.71. Following the transaction, the chief executive officer now directly owns 1,089,070 shares of the company’s stock, valued at approximately $64,374,927.70. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 59,373 shares of company stock valued at $2,706,284. 15.10% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in BEAM. ARK Investment Management LLC lifted its position in Beam Therapeutics by 16.7% during the fourth quarter. ARK Investment Management LLC now owns 7,983,401 shares of the company’s stock valued at $636,197,000 after purchasing an additional 1,141,679 shares during the last quarter. FIL Ltd bought a new stake in Beam Therapeutics during the third quarter valued at approximately $62,221,000. Deep Track Capital LP bought a new stake in Beam Therapeutics during the fourth quarter valued at approximately $55,783,000. BlackRock Inc. lifted its position in Beam Therapeutics by 15.4% during the fourth quarter. BlackRock Inc. now owns 4,062,794 shares of the company’s stock valued at $323,764,000 after purchasing an additional 542,819 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Beam Therapeutics by 61.1% during the third quarter. Goldman Sachs Group Inc. now owns 1,044,082 shares of the company’s stock valued at $90,846,000 after purchasing an additional 396,038 shares during the last quarter. Institutional investors and hedge funds own 68.80% of the company’s stock.

NASDAQ BEAM opened at $29.96 on Monday. Beam Therapeutics has a 52-week low of $29.54 and a 52-week high of $138.52. The company has a 50-day simple moving average of $51.33 and a 200 day simple moving average of $67.93. The company has a market capitalization of $2.10 billion, a PE ratio of -5.04 and a beta of 1.59.

Beam Therapeutics Company Profile (Get Rating)

Beam Therapeutics Inc, a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia.

Read More

Get a free copy of the Zacks research report on Beam Therapeutics (BEAM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Beam Therapeutics (NASDAQ:BEAM)

Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.